ZIZhahirul Islam

Zhahirul Islam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhahirul Islam has a total of 349 co-authors. Here are the top co-authors by number of shared publications:

  • Israt Jahan

    Gut Brain Axis Laboratory, Infectious Diseases Division, icddr,b, Dhaka, Bangladesh

    24 shared publications
  • Hubert P. Endtz

    Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

    18 shared publications
  • Nowshin Papri

    Gut-Brain Axis Laboratory, Infectious Diseases Division, ICDDR, B

    18 shared publications
  • Shoma Hayat

    Gut Brain Axis Laboratory, Infectious Diseases Division, icddr,b, Dhaka, Bangladesh

    17 shared publications
  • Bart C. Jacobs

    Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

    15 shared publications
  • Quazi Deen Mohammad

    Department of Neurology, Specialized Physiotherapy, Rehabilitation Centre (SPRC) and Neurology Hospital, Dhaka, Bangladesh

    12 shared publications

Latest Publications

  • Open Access

    Transformative advances in Guillain–Barré syndrome research

    by Christine M. Szymanski, Ashley M. Rogers, Leandre M. Glendenning, Dee Warmath, Jarrod J. Mousa, Tiffany M. Daugherty, Nadja Zeltner, Jessica L. McAlpine, David R. Tribble, Glen A. Cook, et al.

    The Guillain–Barré Syndrome Innovation Alliance held its inaugural meeting focused on creating treatment solutions for Guillain–Barré syndrome (GBS), an autoimmune disease increasingly recognized as a postinfectious neuropathy and the most common cause of paralysis since vaccines for polio. These collaborators, funded by the Department of War, Congressionally Directed Medical Research Programs, and the National Institute of Allergy and Infectious Diseases, span institutes/universities, including the University of Georgia, Michigan State University, Florida State University, the University of Utrecht, the International Centre for Diarrhoeal Disease Research, and the Uniformed Services University of the Health Sciences. Group efforts span biochemistry, epidemiology, immunology, medicine, microbiology, microbial ecology, glycobiology, neurology, neuroscience, pharmacology, and multiomics data science/computational biology. Our team is committed to the advancement of two core objectives: expanding understanding of biological mechanisms of GBS and developing more efficacious, targeted therapies. We are dedicated to finding alternative therapies for patients unresponsive to intravenous immunoglobulin and to creating affordable options to eliminate financial barriers to care.

  • Open Access

    Alzheimer’s disease and related dementias in South and Southeast Asia: a systematic review and meta-analysis of epidemiology and associated factors

    by Mantaka Rahman, Tamal Saha, Md Abu Jaher Nayeem, Ashiqa Tabassum, Imtiaz Abdullah, Sharmin Sultana, Israt Jahan, Imran Hasan, Shoma Hayat, Nowshin Papri, et al.

    Objectives: Alzheimer’s disease and related dementias (AD/ADRDs) are rising global public health challenges, disproportionately affecting ageing populations. Although higher prevalence estimates have been reported in high-income countries (HICs), the most rapid increase in dementia burden is projected to occur in low- and middle-income countries (LMICs), particularly in South and Southeast Asia. Genetic predisposition and non-modifiable risk factors interplay with vascular, lifestyle and environmental factors, shaping future disease burden. However, evidence from South and Southeast Asia remains fragmented, limiting targeted policy responses. This review systematically synthesises available evidence on prevalence and associated factors to inform prevention and care strategies. Design: Systematic review and meta-analysis of AD/ADRDs prevalence and associated factors related studies from South and Southeast Asia. Data sources: Five electronic databases including PubMed, Scopus, CINAHL, EMBASE, APA PsycNet and hand searching of reference lists up to 1 May 2025. Eligibility criteria for selecting studies: The designed study included observational studies, specifically cross-sectional, casecontrol and cohort designs that reported the epidemiological characteristics and associated factors of AD/ADRDs. Data extraction and synthesis: Study screening, data extraction and methodological assessments were conducted by two independent reviewers. Risk of bias was assessed using the modified Newcastle-Ottawa Scale (mNOS). A restricted maximum likelihood model was used to synthesise results, complemented by synthesis of associated risk factors. Between-study heterogeneity was assessed using I² statistic. Results: A total of 31 studies were included, of which 13 were analysed to estimate pooled prevalence (N=56 340). The methodological quality was good (mean mNOS=7.1, SD 0.99). The pooled age of onset of AD was 70.7 (SD 5.5) years, with one-third (46.3%) of the men surviving for 5 years. The overall estimated prevalence of dementia was 3.0% (95% CI 2.0% to 5.0%, I 2 =98.7%), AD 2.0% (95% CI 1.0% to 4.0%, I 2 =99.0%) and vascular dementia 1.0% (95% CI 0% to 1.0%, I 2 =93.7%). Subgroup analysis showed that AD prevalence was 3.0% in LMICs (95% CI 1.0% to 6.0%) compared with 2.0% in HICs (95% CI 1.0% to 4.0%), and increased to 8.0% after 2010 (95% CI 5.0% to 14.0%) compared with 1.0% before 2000 (95% CI 0% to 2.0%). Additionally, results suggested that older adults had higher odds of AD (OR: 3.98, 95% CI 1.77% to 8.99%), while higher literacy, adequate sleep, periodontal therapy and cognitive stimulation were identified as protective factors. No clear evidence of an association between female gender, family history and AD risk was observed in the pooled analysis. Conclusions: AD affects a substantial and growing proportion of populations in South and Southeast Asia, with marked heterogeneity across settings. Evidence of an upward trend over the time in LMICs poses significant challenges in the coming years. The rising prevalence, associated factors particularly in resource-limited contexts, underscores the need for early-screening in clinical practices and region-specific epidemiological research. PROSPERO registration number: CRD 420251047105.

  • Open Access

    Integrative Bioinformatics Analysis Reveals Convergent Immune Dysregulation in Th17 Cell Differentiation and JAK-STAT Signaling Pathways in Cytomegalovirus Infection and Guillain-Barré Syndrome

    by Jigishu Ahmed, Israt Jahan, Pritha Promita Biswas, Syed Akib Hossain, Rasel Ahmed, Sarah Khurshid, Avizit Das, Asaduzzaman Asad, Zhahirul Islam

    Guillain-Barré Syndrome (GBS) is a post-infectious autoimmune neuropathy and the leading cause of acute flaccid paralysis worldwide, frequently triggered by preceding infections including Campylobacter jejuni and cytomegalovirus (CMV). Unlike C. jejuni -associated GBS, the immunopathogenic mechanisms underlying CMV-associated GBS remain poorly defined. Using an integrative immunoinformatic approach, we separately analyzed disease-associated genes from DisGeNET and publicly available PBMC transcriptomic datasets from CMV-infected and GBS patients from the Gene Expression Omnibus. Differentially expressed genes (DEGs), protein–protein interaction networks, and pathway enrichment analyses were performed to identify shared immune signatures. We identified 245 common DEGs, with hub genes including TNF, IL-1β, IL-6, IL-10, TLR4, and ICAM-1. Pathway analyses revealed significant enrichment of Th17 cell differentiation, JAK–STAT signaling, cytokine–cytokine receptor interaction, and chemokine signaling in both diseases. Despite convergence on shared pathways, key immune genes were predominantly downregulated in CMV infection but upregulated in GBS, suggesting context-dependent pathway regulation across the transition from acute viral infection to post-infectious autoimmunity. These findings provide a mechanistic framework linking CMV-induced immune perturbation and autoimmune neuropathy, and highlight Th17 differentiation and JAK-STAT signaling as central dysregulated pathways in CMV-associated GBS warranting experimental validation.

  • Open Access

    Anxiety and depression and their impact on functional recovery and quality of life in Guillain-Barré syndrome: a prospective cohort study in Bangladesh

    by Nowshin Papri, Ashiqa Tabassum, Tamal Saha, Gulshan Ara, Mantaka Rahman, Shahadat Hossain, M M Jalal Uddin, Md Shahanur Hossain, Liza Akter, M Tasdik Hasan, et al.

    Objectives: Guillain-Barré syndrome (GBS) is an autoimmune polyneuropathy manifested by progressive limb weakness. Anxiety and depression are significant yet under-recognised complications of GBS, particularly in low- and middle-income countries (LMICs). This study examined the proportion and progression of anxiety and depression in Bangladeshi GBS patients and their associations with clinical features, outcomes and quality of life (QoL). Design: A prospective cohort study. Settings: National Institute of Neurosciences and Hospital, Dhaka, Bangladesh. Participants: A total of 148 GBS patients aged ≥18 years diagnosed by National Institute of Neurological Disorders and Stroke criteria for GBS, were recruited within 2 weeks of symptom onset. Primary and secondary outcome measures: Anxiety and depression were evaluated as the primary outcome using the Hospital Anxiety and Depression Scale (HADS) at week 13 and week 26 post-GBS. Secondary outcomes included Medical Research Council sum score, GBS Disability Score, fatigue severity, pain intensity and EuroQol 5-Dimension 5-Level. Statistical analyses involved descriptive summaries, group comparisons, correlation tests and longitudinal assessments by analysis of variance. Results: A total of 111 patients with complete HADS data were analysed (median age 36 years; 71% male). At week 13, 45% had anxiety reducing to 36% at week 26. Depression was 53% at week 13 and 41% at week 26. Baseline bulbar involvement was significantly associated with week 13 depression and week 26 anxiety. Between week 13 and week 26, 27%–30% of patients had persistent symptoms and 13%–16% experienced worsening. Anxiety and depression mostly followed concordant patterns, though 28 patients showed discordant patterns. Elevated mood symptoms were associated with greater fatigue, pain and reduced QoL. Conclusions: Anxiety and depression are common and persistent in GBS adversely affecting recovery and QoL. Mental health monitoring and targeted support should be integrated into GBS management, especially in LMIC settings.

  • Open Access

    Distinct gut microbial signatures associated with disease onset and clinical course in Guillain–Barre syndrome

    by Israt Jahan, Asaduzzaman Asad, Md. Abu Jaher Nayeem, Rasel Ahmed, Ruma Begum, Mohammad Jubair, Quazi Deen Mohammad, Sonja E. Leonhard, Bart C. Jacobs, Hubert P. Endtz, et al.

  • Impact of Gut Microbiota Dysbiosis in Treatment Outcomes of Guillain‐Barré Syndrome

    by Shoma Hayat, Md. Abu Jaher Nayeem, Asaduzzaman Asad, Md. Golam Mostafa, Ruma Begum, Moriam Akter Munni, Ayesha Akter Anjuman, Saima Akhter Sadia, Ismat Jahan Upama, Imran Hasan, et al.

    Background and Aims: The gut‐microbiota plays a significant role in neuro‐autoimmune diseases, like Guillain‐Barré syndrome (GBS), a post‐infectious disorder of the peripheral nervous system (PNS). By altering host immunity, gut dysbiosis may impact the standard therapeutic efficacy of intravenous immunoglobulin (IVIg) and plasma exchange (PE) and thereby, disease progression in GBS. In this study, we investigated the impact of gut‐microbiota diversity on therapeutic outcomes of IVIg and PE in patients with GBS. Methods: We enrolled 60 patients with GBS categorized into three treatment groups: IVIg‐treated, PE, and supportive‐care along with 60 age‐sex‐matched healthy controls from Bangladesh. Fecal microbial DNA was extracted at different timepoints and sequenced. Clinical and sequenced data were analyzed using the Qiime2‐Dada2 pipeline. Results: Gut‐microbial diversity significantly differed in patients with GBS before and after treatment (Shannon: p = 0.037; Evenness: p = 0.012), particularly in IVIg‐treated patients, showing significant changes after 6‐month treatment (Shannon: p = 0.034; Evenness: p = 0.011). Beta diversity indicated microbiota restoration in IVIg‐treated patients toward a healthy state after treatment ( p ≤ 0.001). Phylum Actinobacteriota ( p = 0.026), genera Bifidobacterium ( p = 0.006), and Enterococcus ( p ≤ 0.0001) were relatively abundant in severe patients. Mechanically ventilated patients showed significant gut‐microbial diversity (Unweighted‐UniFrac; p ≤ 0.001). Biomarker analysis identified a higher abundance of Eubacterium, Bacteroides, Escherichia‐Shigella , and Actinomyces in GBS patients. Interpretation: Our exploratory study indicates that gut microbiota dysbiosis is associated with GBS severity and IVIg‐treatment outcomes. IVIg‐treatment promoted partial restoration of microbial diversity, suggesting a potential immunomodulatory effect mediated through the microbiota. Further studies using meta‐transcriptomics are warranted to define functional consequences of microbial shifts in treatment responses of GBS.

  • Open Access

    Challenges in Diagnosis and Management of Crohn's Disease in Bangladesh With Long Term Follow‐Up

    by Imtiaz Abdullah, Imran Hasan, Mantaka Rahman, Shoma Hayat, Nowshin Papri, Nusrat Fatema, Ahmedul Kabir, Zhahirul Islam

    Crohn's disease (CD) is a chronic autoimmune inflammatory bowel disease (IBD) with significant diagnostic and therapeutic challenges. We reported a case of a 20‐year‐old Bangladeshi male with an 8‐month history of severe upper abdominal pain, bowel discomfort, and intermittent low‐grade fever. Initial investigations showed mild anemia and elevated inflammatory markers. Magnetic resonance enterography revealed distal small bowel thickening, suggestive of IBD. Colonoscopy and biopsy confirmed chronic ileitis without granulomas and an ulcer at the terminal ileum. Despite the absence of granulomas, clinical symptoms, elevated fecal calprotectin, and high C‐reactive protein (CRP) led to a diagnosis of CD. The disease later progressed to a perianal abscess, a fistulizing complication. The patient received three doses of infliximab but subsequently discontinued therapy. He remained untreated for 3‐years and subsequently developed an intestinal perforation requiring right hemicolectomy with ileostomy. Following ileostomy reversal, adalimumab was advised. This case highlighted the diagnostic and therapeutic challenges of CD in Bangladesh.

  • Open Access

    Molecular epidemiology of Campylobacter jejuni associated with Guillain–Barré syndrome

    by Shoma Hayat, Md. Golam Mostafa, Md. Abu Jaher Nayeem, Ruma Begum, Ayesha Akter Anjuman, Saima Akhter Sadia, Imran Hasan, Asaduzzaman Asad, Zhahirul Islam

    Campylobacter jejuni is the leading cause of bacterial gastroenteritis and its post-infectious sequelae, Guillain-Barré syndrome (GBS). Disease epidemiology of campylobacteriosis differs between high- and low-income countries. The molecular epidemiology of GBS-associated C. jejuni strains has not been thoroughly studied to understand its population dynamics and unique genomic features. We investigated a genome-based epidemiological analysis of 90 GBS-associated C. jejuni strains from 10 different countries to elucidate bacterial genomic features and epidemiological patterns related to GBS induction. We found 11 clonal complexes (CC) and 25 sequence types (STs) with two prevalent lineages, CC-362 (ST-2993) and CC-22(ST-22). SNP-based phylogenetic analysis revealed, the first sequenced C. jejuni (CC-22) from USA was genetically associated with strains from Bangladesh, Mexico, and China. Lipo-oligosaccharide (LOS) class A was prevalent worldwide (63%). In Bangladesh, 32% (9/28) of sialyltransferase cstII-genes harbored a Threonine at 51st-position, compared to China (60%, 6/10), USA (100%, 2/2), and Netherlands (67%, 4/6). Type-VI secretion system was enriched in Bangladesh (11/38, 29%). Among C. jejuni-integrated elements, CJIE-1 was most common (27/90, 30%). Phase variation was significantly higher in CC-403 strains. These diversified genomic characteristics of GBS-associated C. jejuni enhance our understanding of its pathogenic virulence features and linked epidemiological-pattern in Bangladesh and worldwide.


  • Climatic and Geographic Variations of Antecedent Infections in Guillain–Barré Syndrome: A Long‐Term Longitudinal Analysis From Bangladesh

    by Mantaka Rahman, Nowshin Papri, Asif Mohammed, Imran Hasan, Sharmin Sultana, Israt Jahan, Shoma Hayat, Zhahirul Islam

    Background and Aims: Guillain–Barré syndrome (GBS) is an acute post‐infectious autoimmune neuropathy, frequently triggered by antecedent infections. While climate influences the seasonality and distribution of infections, its role in triggering GBS remains underexplored. We aimed to evaluate the impact of climatic and geographical variations on infections preceding GBS in Bangladesh. Methods: Five hundred and sixty‐six GBS patients were enrolled from four prospective cohorts (2010–2024). Antecedent events were recorded within 4 weeks of weakness onset. Meteorological data were retrieved from the World Bank's Climate Change Knowledge Portal (2010–2020) and Bangladesh Meteorological Department (2021–2024). Patients were categorized by regions (northern, central, southwestern, and eastern), seasons (summer, autumn, winter, spring). Analysis were performed in R using chi‐square, t ‐tests, Kaplan–Meier, and multivariable logistic regression. Results: Among 566 patients (69% male, median age: 31 years). Antecedent events were reported in 70%, predominantly GE (46%) and URTI (19%). The axonal subtype predominated (64%), with 31% receiving intravenous immunoglobulin or plasma exchange. GE was associated with higher disability (GBS‐DS = 4, 61% vs. 46%, p = 0.014 ) and cranial nerve involvement (57% vs. 43%, p = 0.017) compared to URTI. GE peaked during spring (31%) and URTI in winter (35%, p = 0.009), with no subtype‐season association after adjustment ( p = 0.180). GE occurred more at higher mean temperatures (26.06°C vs. 25.05°C, p = 0.048) and at higher precipitation (162.65 mm vs. 105.04 mm, p = 0.0001). GE cases correlated positively, while URTI inversely, with temperature ( r s = 0.185) and precipitation ( r s = 0.053). Interpretations: Warmer temperature and higher precipitation, particularly spring and summer, favor GE‐related GBS. Further studies are warranted to explore climate‐sensitive infectious triggers of GBS in Bangladesh.

  • Prognostic Nutritional Index as a Biomarker of Disease Severity and Long‐Term Outcome in Guillain–Barré Syndrome

    by Pritha Promita Biswas, Israt Jahan, Jigishu Ahmed, Nowshin Papri, Rasel Ahmed, Sarah Khurshid, Quazi Deen Mohammad, Gulshan Ara, Zhahirul Islam

    Background and Aims: Guillain–Barré syndrome (GBS) exhibits clinical heterogeneity and variable progression. In low‐resource settings, malnutrition and limited treatment worsen prognosis, underscoring the need for a simple prognostic tool. This study evaluated the Prognostic Nutritional Index (PNI) and Nutritional Risk Index (NRI) in relation to GBS severity and long‐term outcomes, comparing their predictive value with standard prognostic indicators. Methods: An observational cohort study of 252 GBS patients enrolled between 2019 and 2024 was conducted. PNI and NRI were calculated using serum albumin, lymphocyte count, and body weight. The GBS‐disability score (GBS‐DS) assessed baseline severity and 26‐week outcomes. Statistical analysis included Chi‐square tests, Mann–Whitney U tests, Spearman's ρ , and logistic regression to identify predictors. ROC analysis determined optimal PNI cut‐offs, confirmed by Kaplan–Meier survival curves. Results: PNI, unlike NRI, was significantly reduced in severe GBS (GBS‐DS > 3) compared to mild/moderate GBS (GBS‐DS ≤ 3). PNI correlated with GBS‐DS ( ρ = −0.62), MRC sum score ( ρ = 0.5), hemoglobin ( ρ = 0.53), and neutrophil count ( ρ = −0.35) (all p < 0.0001). PNI independently predicted disease severity (odds ratio [OR] = 0.91; p = 0.036) and 26‐week outcomes (OR = 0.93; p = 0.033). Area under the ROC curve (AUC) was 0.769 for severity and 0.719 for 26‐week outcomes. PNI cut‐offs of 49.395 and 45.72 predicted severe GBS and long‐term poor outcome, respectively. Kaplan Meier analysis confirmed patients with PNI < 45.72 required a longer time to gain independent locomotion ( p < 0.0001). Interpretation: Lower PNI, but not NRI, is associated with greater GBS severity and poor long‐term outcomes. PNI independently predicted disease severity and 26‐week outcomes, with specific cut‐offs identifying patients requiring longer recovery, supporting its prognostic utility.